90,400 Shares in Nektar Therapeutics $NKTR Acquired by ACT Capital Partners L.P.

ACT Capital Partners L.P. bought a new stake in shares of Nektar Therapeutics (NASDAQ:NKTR) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 90,400 shares of the biopharmaceutical company’s stock, valued at approximately $5,473,000. Nektar Therapeutics comprises approximately 3.6% of ACT Capital Partners L.P.’s investment portfolio, making the stock its 11th biggest holding. ACT Capital Partners L.P. owned 0.26% of Nektar Therapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. KBC Group NV bought a new stake in Nektar Therapeutics in the first quarter worth $52,000. State of Wyoming purchased a new position in Nektar Therapeutics during the first quarter worth $67,000. Sterling Capital Management LLC boosted its stake in Nektar Therapeutics by 507.2% during the third quarter. Sterling Capital Management LLC now owns 1,099 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 918 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Nektar Therapeutics by 35.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,160 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 560 shares during the period. Finally, Great Lakes Advisors LLC bought a new position in Nektar Therapeutics during the second quarter valued at $206,000. Hedge funds and other institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics News Summary

These are some of the NKTR news items that stood out recently:

• Positive Sentiment: Nektar’s loss of $1.63 per share was narrower than analysts’ estimates. The company also said it had initiated all three Phase 3 ZENITH trials for rezpegaldesleukin in atopic dermatitis, with an alopecia areata trial planned for December. Zacks Q3 results and outlook
• Positive Sentiment: The company reported $952.9 million in cash and marketable securities at quarter-end, providing resources to advance its clinical programs. Nektar Q3 financial results
• Negative Sentiment: Nektar cut its 2026 revenue outlook, a key reason shares were reported down 4.5%. Quarterly revenue of $9.4 million missed the roughly $10.3 million consensus and declined from $11.8 million a year earlier. Zacks Q3 results and outlook

Analysts Set New Price Targets

Several brokerages have recently weighed in on NKTR. Wall Street Zen downgraded shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Leerink Partners started coverage on shares of Nektar Therapeutics in a research note on Monday, October 12th. They set an “outperform” rating and a $130.00 price target for the company. Raymond James Financial began coverage on shares of Nektar Therapeutics in a report on Friday, October 9th. They set a “market perform” rating on the stock. TD Cowen raised shares of Nektar Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Finally, Wedbush decreased their price objective on shares of Nektar Therapeutics from $80.00 to $50.00 and set a “neutral” rating for the company in a research note on Wednesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $130.67.

Insider Buying and Selling

In other news, CEO Howard Robin sold 418 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $71.98, for a total transaction of $30,087.64. Following the transaction, the chief executive officer directly owned 54,627 shares of the company’s stock, valued at approximately $3,932,051.46. This trade represents a 0.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.50% of the stock is owned by corporate insiders.

Nektar Therapeutics Stock Performance

NKTR stock traded up $0.02 during midday trading on Friday, reaching $37.27. The company’s stock had a trading volume of 695,154 shares, compared to its average volume of 647,392. Nektar Therapeutics has a 1 year low of $33.40 and a 1 year high of $109.00. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of -5.77 and a beta of 1.44. The stock has a fifty day simple moving average of $48.47 and a two-hundred day simple moving average of $64.54.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Thursday, November 12th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.07) by $0.44. The firm had revenue of $9.39 million during the quarter, compared to analyst estimates of $10.27 million. Nektar Therapeutics had a negative net margin of 339.67% and a negative return on equity of 33.89%. As a group, analysts forecast that Nektar Therapeutics will post -8.08 EPS for the current fiscal year.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.